drug
VP-001
Phase 2updated 3mo agoby PYC Therapeutics Ltd
Phase 2community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying VP-001
- phase1SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects
- phase1MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
- phase2Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent
- phase2A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
- phase1First in Human Study of RVP-001, a New Manganese Based MRI Contrast Agent
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that